Faruqi & Faruqi, LLP is investigating claims against Grail, Inc. following the company's announcement that its NHS-Galleri cancer screening trial did not meet its primary endpoint of significantly reducing late-stage cancers. The trial results revealed on February 19, 2026, led to a sharp 50% drop in Grail's stock price. The law firm reminds investors who bought Grail shares between May 13, 2025, and February 19, 2026, of the August 4, 2026 deadline to seek lead plaintiff status in the class action lawsuit. Investors are encouraged to contact the firm to discuss their legal options and potential recovery.
Shield appointed Michelle Clark, former HSBC surveillance leader, as Global Communications Surveillance Expert to enhance its AI-driven product strategy. Clark's 20+ years in global banking and expertise in regulatory compliance and AI innovation wil...
Phonak has introduced Roger On Sphere™, the world's first remote microphone using AI to separate speech from background noise in real time. This device enhances communication for people with hearing loss in noisy environments like restaurants and mee...
Southern Company, operating through Georgia Power, Alabama Power, and Mississippi Power, reported a data breach compromising customer personal information including names, addresses, Social Security numbers, and financial details. This breach raises ...
Intel's stock price has almost tripled in 2026, showing strong recent performance. However, a $10,000 investment in Intel made in 2016 would still be worth less than if it had been invested in the S&P 500 index. This highlights that despite recent ga...
The article evaluates the iShares JPMorgan USD Emerging Markets Bond ETF (EMB) as an investment option, focusing on its market price, yield, and risk-return profile amid current macroeconomic conditions. The author, with extensive financial experienc...
